KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab + sotorasib Sensitive: B - Late Trials ESMO Asia 2023 - 6 days (New B) panitumumab + sotorasib Sensitive : B ESMO Asia 2023 - 6d	panitumumab + sotorasib Sensitive: B - Late Trials ESMO Asia 2023 - 6 days panitumumab + sotorasib Sensitive : B ESMO Asia 2023 - 6 days - (New B)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	adagrasib Sensitive: A1 - Approval Mirati Therapeutics Press Release - 3 weeks (New C3) adagrasib Sensitive : A1 Mirati Therapeutics Press Release - 3wk	adagrasib Sensitive: A1 - Approval Mirati Therapeutics Press Release - 3 weeks adagrasib Sensitive : A1 Mirati Therapeutics Press Release - 3 weeks - (New C3)
KRAS G12C	Multiple Myeloma	KRAS G12C	Multiple Myeloma	MRTX1257 Sensitive: D – Preclinical ASH 2023 - 4 weeks (New D) MRTX1257 Sensitive : D ASH 2023 - 4wk	MRTX1257 Sensitive: D – Preclinical ASH 2023 - 4 weeks MRTX1257 Sensitive : D ASH 2023 - 4 weeks - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	RMC-4550 + RM-029 Sensitive: D – Preclinical SITC 2023 - 4 weeks (New D) RMC-4550 + RM-029 Sensitive : D SITC 2023 - 4wk	RMC-4550 + RM-029 Sensitive: D – Preclinical SITC 2023 - 4 weeks RMC-4550 + RM-029 Sensitive : D SITC 2023 - 4 weeks - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	adagrasib Sensitive: A2 - Guideline adagrasib Sensitive : A2	adagrasib Sensitive: A2 - Guideline adagrasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	panitumumab + sotorasib Sensitive: A2 - Guideline panitumumab + sotorasib Sensitive : A2	panitumumab + sotorasib Sensitive: A2 - Guideline panitumumab + sotorasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	cetuximab + sotorasib Sensitive: A2 - Guideline cetuximab + sotorasib Sensitive : A2	cetuximab + sotorasib Sensitive: A2 - Guideline cetuximab + sotorasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	panitumumab + adagrasib Sensitive: A2 - Guideline panitumumab + adagrasib Sensitive : A2	panitumumab + adagrasib Sensitive: A2 - Guideline panitumumab + adagrasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	cetuximab + adagrasib Sensitive: A2 - Guideline cetuximab + adagrasib Sensitive : A2	cetuximab + adagrasib Sensitive: A2 - Guideline cetuximab + adagrasib Sensitive : A2
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	panitumumab + sotorasib Sensitive: A2 - Guideline panitumumab + sotorasib Sensitive : A2	panitumumab + sotorasib Sensitive: A2 - Guideline panitumumab + sotorasib Sensitive : A2
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	cetuximab + sotorasib Sensitive: A2 - Guideline cetuximab + sotorasib Sensitive : A2	cetuximab + sotorasib Sensitive: A2 - Guideline cetuximab + sotorasib Sensitive : A2
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	cetuximab + adagrasib Sensitive: A2 - Guideline cetuximab + adagrasib Sensitive : A2	cetuximab + adagrasib Sensitive: A2 - Guideline cetuximab + adagrasib Sensitive : A2
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	panitumumab + adagrasib Sensitive: A2 - Guideline panitumumab + adagrasib Sensitive : A2	panitumumab + adagrasib Sensitive: A2 - Guideline panitumumab + adagrasib Sensitive : A2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab + adagrasib Sensitive: B - Late Trials cetuximab + adagrasib Sensitive : B	cetuximab + adagrasib Sensitive: B - Late Trials cetuximab + adagrasib Sensitive : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + BMS-986466 Sensitive: B - Late Trials sotorasib + BMS-986466 Sensitive : B	sotorasib + BMS-986466 Sensitive: B - Late Trials sotorasib + BMS-986466 Sensitive : B
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	JAB-21822 Sensitive: B - Late Trials JAB-21822 Sensitive : B	JAB-21822 Sensitive: B - Late Trials JAB-21822 Sensitive : B
KRAS G12C	Ampulla of Vater Carcinoma	KRAS G12C	Ampulla of Vater Carcinoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Cholangiocarcinoma	KRAS G12C	Cholangiocarcinoma	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Ovarian Cancer	KRAS G12C	Ovarian Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Melanoma	KRAS G12C	Melanoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1

KRAS G12C

Associations